C

Colossal

Gene editing for de-extinction of megafauna

Research Associate/Senior Research Associate - Genome Engineering

Full-TimeUpdated on 10/16/2026
No salary listed
Mid
Bachelor's, Master's
Dallas, TX, USA
In PersonOn-site in Dallas; relocation assistance is available.
Biology & BiotechTranslational Research & Bench Biology

About the job

Requirements
  • A Bachelor of Arts or Bachelor of Science, or a Master of Arts or Master of Science, in molecular biology, genetics, biotechnology, bioengineering, or a related field is required.
  • Demonstrated hands-on molecular biology research experience, including cloning, polymerase chain reaction (PCR), plasmid preparation, and sequence verification is required.
  • Practical experience supporting CRISPR/Cas9 genome editing and multiplex editing experiments or reagent workflows is required.
  • Experience preparing, handling, and quality-controlling DNA and/or RNA editing reagents is required.
  • Ability to independently execute established protocols, troubleshoot routine technical problems, and contribute immediately with limited training is required.
  • Strong organizational skills, attention to detail, and written and oral communication skills are required.
Responsibilities
  • Generate and quality-control genome editing reagents, including single-guide RNAs (sgRNAs), prime editing guide RNAs (pegRNAs), donor DNA templates, plasmids, and expression constructs.
  • Perform molecular cloning, DNA assembly, bacterial culture, plasmid purification, polymerase chain reaction (PCR), and sequence verification.
  • Support preparation and quality control of RNA reagents, including in vitro transcription and purification where applicable.
  • Prepare and track reagent sets for multiplex genome editing experiments, maintaining accurate construct and sample identities.
  • Work with Genome Engineering scientists to implement and troubleshoot CRISPR/Cas9, prime editing, and base editing designs.
  • Transfer validated reagents and clear experimental documentation to Cell Engineering colleagues for transfection and downstream cellular workflows.
  • Perform PCR-based genotyping, prepare samples for sequencing, and support analysis of single-locus and multiplex editing outcomes.
  • Maintain accurate electronic laboratory records, reagent inventories, and quality-control documentation in an electronic laboratory notebook (ELN).
  • Organize concurrent experiments, communicate results, and proactively improve workflows.
Desired Qualifications
  • Hands-on experience with prime editing and/or base editing reagents and workflows.
  • Experience designing or preparing pegRNAs, modified guide RNAs, or homology-directed repair (HDR) donors.
  • Experience with in vitro transcription, RNA purification, or nucleic acid quality control (QC).
  • Experience with sequencing-based genotyping and analysis of multiplex edits.
  • Experience with electronic laboratory notebooks and cross-functional reagent handoffs.

About the company

Colossal develops gene editing approaches to revive extinct or endangered species and restore ecological balance. It collects viable DNA samples and edits genes to rebuild traits of lost megafauna, with Woolly Mammoth as a leading project. Its technology translates into practical applications for species recovery and conservation, aiming to kickstart biodiversity and support the biology economy. Distinctive aspects include a focus on de-extinction tied to ecological restoration, leadership from Ben Lamm and George Church, and a strategy that links scientific capability with real-world ecological and economic benefits. The company’s goal is to reawaken lost wilds to help ecosystems recover and allow humanity to coexist with a healthier planet.

Company Size

51-200

Company Stage

Series C

Total Funding

$625M

Headquarters

Dallas, Texas

Founded

2021

Get referred to Colossal

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2026 USFWS agreement covers 2,300 ESA species and opens federal sampling.
  • August 2026 Paw Patrol campaign expands consumer reach and conservation recruitment.
  • 2026 publications and mammoth-cell edits validate the platform's scientific throughput.

What critics are saying

  • Critics call dire wolves gray-wolf hybrids; that credibility gap threatens future fundraising.
  • Elephant surrogacy, cloned embryos, and artificial eggs face welfare, failure, and regulatory backlash.
  • A mammoth accident or habitat mismatch would trigger an existential de-extinction collapse.

What makes Colossal unique

  • Colossal combines de-extinction branding with conservation biobanks and cloning infrastructure.
  • Ben Lamm and George Church pair celebrity fundraising with multiplex CRISPR credibility.
  • BioVault partnerships with U.S. Fish and Wildlife and Dubai create global specimen access.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Unlimited Paid Time Off
  • Flexible Spending Account/Flexible Spending Account
  • 401(k) Company Match
  • Paid Parental Leave
  • Education Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

1%

2 year growth

0%
Channel NewsAsia
Oct 14th, 2026
US company announces progress toward resurrecting the extinct dodo.

US company announces progress toward resurrecting the extinct dodo. 15 Oct 2026 05:03AM Add CNA as a trusted source to help Google better understand and surface our content in search results. Oct 14: A US biotech company says it is making progress toward its goal of resurrecting the dodo, the famous flightless bird with a large hooked beak, and returning it to its native Indian Ocean island of Mauritius, where humans drove it to extinction in the 17th century. Dallas-based Colossal Biosciences said on Wednesday it has used a newly developed AI platform to identify genetic changes that may be responsible for the dodo's distinctive craniofacial traits as its scientists pursue gene-editing targets to bring back this lost species. Colossal is planning to perform gene-editing to bring dodo traits into the cells of its closest living relative, the Nicobar pigeon. Native to some Southeast Asian islands, the Nicobar pigeon is known for its shimmering green and copper feathers and, unlike the dodo, can fly. The company said it is in the final stages of its analysis of the dodo genome, now filled to 95 per cent. It also said it has made an advance that should shorten the time needed to test whether a genetic edit produces the desired trait. The company did not announce a timeframe for hatching a dodo. Colossal says it is dedicated to "de-extinction" - resurrecting vanished species. Last year, it said it had genetically engineered the dire wolf by editing the genes of the gray wolf, the extinct Ice Age predator's closest living relative, to add dire wolf traits. Besides the dodo and dire wolf, Colossal has four other species on its de-extinction list: the woolly mammoth; the thylacine, also called the Tasmanian tiger; the bluebuck antelope; and the moa, a large flightless bird. "The dodo is the world's best-known symbol of extinction caused by people. It disappeared within decades of humans arriving on Mauritius, largely because of the introduction of invasive species like rats and other animals they brought. Bringing it back shows extinction doesn't have to be permanent," Ben Lamm, Colossal's CEO and co-founder, told Reuters. "The big hurdles ahead are proving which genetic changes really matter, making many of those edits in a bird and passing them to the next generation, and preparing a safe home for dodos on Mauritius," Lamm said. The dodo was a ground-nesting bird about 3 feet (1 metre) tall and weighing up to about 50 pounds (23 kg). Having never encountered humans, dodos exhibited no fear of the people who reached Mauritius in the 16th century. Pressured by invasive species and human hunting, the last living dodo was seen in 1662. It has remained alive in popular culture including in Lewis Carroll's book "Alice's Adventures in Wonderland." GENOMORPH PLATFORM Ancient DNA is always broken into small pieces, so no ancient genome is perfectly complete, including that of the dodo. The new AI platform Colossal built is called GenoMorph. "The challenge was scientists only have one complete dodo genome, making it difficult to distinguish the genetic differences that made the dodo unique from ordinary genetic variation. GenoMorph effectively acts as a 'treasure map' for the dodo genome, narrowing hundreds of thousands of possible genetic changes into the targets most likely to explain its iconic beak and facial structure," Lamm said. Beth Shapiro, Colossal's chief science officer, said GenoMorph finds likely gene-editing targets for species with very little surviving DNA. Normally scientists compare many genomes from one species to find the genes behind a trait, but this is not possible with the dodo, Shapiro said. "So instead, GenoMorph studies how skulls and beaks develop across more than 70 living bird species and learns which genetic switches control their shape. It gave us a shortlist of about 2,300 candidates linked to beak size and shape. These targets are now being validated in the lab," Shapiro said. Colossal said it has expanded its colony of Nicobar pigeons in Texas to 36 birds following successful breeding among established pairs. It said this should help in studying Nicobar pigeon development, reproduction and genetics. Lamm said the company is working with Mauritian scientists, conservation groups and the Mauritius government on what bringing the dodo back to its native land might look like. "Getting Mauritius ready for dodos also means removing invasive predators and restoring habitat, which helps the native species living there now," Lamm said. "No release sites will be chosen until the ecological work and community consultation are finalized, but it is Colossal's goal to put our dodos back into their natural habitats in Mauritius."

TechCrunch
Oct 14th, 2026
Colossal unveils GenoMorph AI, finding 2,300 gene editing targets to bring back the dodo

Colossal Biosciences has launched GenoMorph, an AI platform that helps identify genes to edit when bringing back extinct species with little genetic data. The company is using it in its dodo project, where it has just one dodo genome, against 100 for its woolly mammoth work. GenoMorph combines developmental data from chickens, quail, ducks, and pigeons with genetic information and 3D skull measurements from more than 70 bird species. It has found about 2,300 promising editing targets for the dodo's skull and face, which the company can now test in the lab. Colossal also said its Nicobar pigeon colony, the dodo's closest living relative, now has 36 birds. It has created the cells that become eggs and sperm. XPRIZE founder and Colossal investor Peter Diamandis announced a new VC firm, NeoGenesis Capital, to back companies using Colossal's platform.

CR Bookings
Oct 14th, 2026
Colossal Biosciences announces new AI platform to help accelerate de-extinction efforts.

Colossal Biosciences announces new AI platform to help accelerate de-extinction efforts. admin October 14, 2026 Colossal announced a new AI platform to help accelerate its de-extinction efforts and Peter Diamandis has launched... Colossal announced a new AI platform to help accelerate its de-extinction efforts and Peter Diamandis has launched a new fund to back startups who use it.

CNBC
Oct 10th, 2026
Colossal's de-extinction push: dire wolf pups, mammoth plans and a $10.2B valuation

Colossal Biosciences, a startup working to revive extinct species, has produced three genetically engineered dire wolf pups and is working on the woolly mammoth. Chief executive officer Ben Lamm told CNBC the company aims for a mammoth birth in the 2030s. Colossal used AI models to rebuild the dire wolf genome from ancient DNA, then edited gray wolf cells to create embryos. Domestic dogs served as surrogate mothers. Skeptics say the pups are modified gray wolves; Lamm called that a "semantic argument." Lamm says the work could advance gene therapies, conservation, and climate efforts. Colossal announced a $200 million Series C round in July, led by TWG Global, at a $10.2 billion valuation. It has raised more than $435 million in total.

Moneycontrol
Sep 27th, 2026
Real-life Mammoths by the 2030s? Scientists plan to bring back the Ice Age giant with AI.

Real-life Mammoths by the 2030s? Scientists plan to bring back the Ice Age giant with AI. Could woolly mammoths return by the 2030s? Discover how scientists are using AI, gene editing and reproductive technology to create mammoth-like elephants. September 27, 2026 / 13:43 IST Scientists are using AI and gene editing to develop a mammoth-like elephant by 2030. (Image: Canva) * Company aims to create a mammoth-like elephant. * AI to help identify genetic traits for cold adaptation. * Project faces challenges; timeline shifted to 2030s. Did our AI summary help? The woolly mammoth disappeared thousands of years ago. Now, a biotechnology company is attempting to recreate some of its defining characteristics in a living elephant. Colossal Biosciences is developing a cold-adapted, mammoth-like elephant by introducing selected genetic traits associated with the extinct species. The project has attracted attention for its ambition to bring an Ice Age animal back into the modern world. However, the goal is not to produce an exact copy of a woolly mammoth. Why are scientists trying to bring back woolly mammoths? Woolly mammoths once roamed cold environments across parts of the Northern Hemisphere. Their thick coats, insulating fat and other adaptations helped them survive harsh conditions. Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated! Watch. Must listen. * On Saturdays Find the best of Al News in one place, specially curated for you every weekend. * Daily-Weekdays Stay on top of the latest tech trends and biggest startup news.